Cerebral Cavernous Malformation: From Genetics to Pharmacotherapy
Author Information
Author(s): Zhang Zhuangzhuang, Deng Jianwen, Sun Weiping, Wang Zhaoxia
Primary Institution: Peking University First Hospital
Hypothesis
This review aims to explore the genetic mutations, molecular mechanisms, and pharmacological interventions related to cerebral cavernous malformation (CCM).
Conclusion
Understanding the molecular mechanisms underlying CCM offers potential for targeted therapies.
Supporting Evidence
- Germline and somatic mutations mediate the onset and development of CCM through several molecular pathways.
- Medications such as statins, fasudil, rapamycin, and propranolol can alleviate CCM symptoms or hinder its progression.
- Further research into novel mutations and treatment strategies is essential for improving patient outcomes.
Takeaway
Cerebral cavernous malformation is a condition caused by genetic mutations that lead to abnormal blood vessel formations in the brain, and researchers are looking for ways to treat it with medications.
Methodology
Literatures on the genetic mechanisms and pharmacological treatments of CCM can be searched in PubMed and Web of Science.
Limitations
The mechanisms driving CCM remain incompletely understood, and no drugs have been developed that can cure or prevent CCM.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website